5-Fluorouracil (5-FU) is a chemotherapeutic agent commonly used to treat esophageal squamous cell carcinoma (ESCC), but acquisition of chemoresistance frequently occurs and the underlying mechanisms are not fully understood. We found that mi-croRNA (miR)-338-5p was underexpressed in ESCC cells with acquired 5-FU chemoresistance. Forced expression of miR-338-5p in these cells resulted in downregulation of Id-1, and restoration of both in vitro and in vivo sensitivity to 5-FU treatment. The effects were abolished by reexpression of Id-1. In contrast, miR-338-5p knockdown induced 5-FU resistance in chemosensitive esophageal cell lines, and knockdown of both miR-338-5p and Id-1 resensitized the cells to 5-FU. In addition, miR-338-5p had suppressive effects on migration and invasion of ESCC cells. Luciferase reporter assay confirmed a direct interaction between miR-338-5p and the 3′-UTR of Id-1. We also found that miR-338-5p was significantly downregulated in tumor tissue and serum samples of patients with ESCC. Notably, low serum miR-338-5p expression level was associated with poorer survival and poor response to 5-FU/cisplatin-based neoadjuvant chemoradiotherapy. In summary, we found that miR-338-5p can modulate 5-FU chemoresistance and inhibit invasion-related functions in ESCC by negatively regulating Id-1, and that serum miR-338-5p could be a novel noninvasive prognostic and predictive biomarker in ESCC.
| INTRODUC TI ON
Esophageal squamous cell carcinoma constitutes more than 80% of esophageal cancer cases worldwide. 1, 2 Preoperative chemoradiotherapy with 5-FU and cisplatin has become a standard treatment for advanced resectable ESCC. However, resistance to therapy is a key factor responsible for the overall low survival rate. 3 The underlying mechanisms of chemoresistance in ESCC are still not fully understood.
Recent studies highlight the involvement of miRNAs as tumor suppressors or oncogenes in tumor progression. 4 MicroRNAs form a double-stranded complex with target mRNAs by binding to the 3′-UTR, and consequently reduce the target protein expression either by suppressing gene translation or by degrading the mRNA. 5 MicroRNAs are increasingly recognized as useful diagnostic and prognostic biomarkers. Circulating miRNAs, in particular, are ideal biomarkers for continuous monitoring of cancer progression and cancer surveillance because they are present in a cell-free form associated with lipids or lipoproteins in the blood, and are therefore protected from degradation. 6, 7 Increasing evidence supports the involvement of miRNAs in chemoresistance. For example, gain of miR-241-3p expression enhanced sensitivity of ESCC cells to cisplatin, 8 whereas loss of miR-445-3p had a similar effect. 9 It was also reported that modulation of miR-130a-3p and miR-148a-3p in both directions increased the sensitivity of ESCC cells to 5-FU and cisplatin. 10 We found that ectopic overexpression of miR-377, which targeted CD133 and suppressed cancer stemness, had a chemosensitizing effect on ESCC cells. 11 More recently, we identified the miR-29c-3p/FBXO31-p38 axis as a key regulator of chemoresistance in ESCC. 12 Our previous studies also showed that Id-1 and its downstream PI3K/Akt pathway play an essential role in promoting chemoresistance in ESCC. [13] [14] [15] The significance of Id-1 in ESCC is evident from its frequent aberrant overexpression in ESCC tumors, and the association between its expression level and poor prognosis. 15, 16 As little is known about the mechanisms that regulate Id-1 expression and the strategies by which Id-1 can be inhibited, this study aimed to identify novel and clinically relevant miRNA(s) that can suppress Id-1 and regulate chemoresistance in ESCC. Herein, we present data based on in vitro and in vivo functional experiments, as well as analyses of clinical samples, to show that miR-338-5p is downregulated in ESCC, and that it regulates chemoresistance and invasion-related functions in ESCC cells by negatively regulating Id-1. The potential of circulating miR-338-5p as a noninvasive biomarker was also explored.
| MATERIAL S AND ME THODS

| Cell lines and transfections
Esophageal squamous cell carcinoma cell lines KYSE410, KYSE150, and KYSE270, 17 obtained from DSMZ, were maintained in RPMI-1640 (Sigma) supplemented with 10% FBS (Invitrogen). The 293T cell line, and the ESCC cell line T.Tn 18 obtained from Dr Hitoshi Kawamata (Dokkyo University School of Medicine, Tochigi, Japan), were maintained in DMEM/F12 (Invitrogen) supplemented with 10% FBS. All cell lines were authenticated using short tandem repeat analysis. The FR sublines KYSE410FR and KYSE150FR were generated from parental cell lines (KYSE410 and KYSE150 cells, respectively) by exposing them gradually to increasing concentration of 5-FU (up to 80 μmol/L) over a period of 18 months. 15 Transfection and transduction were carried out as described previously. 15 Vectors for transient expression of miR-338-5p (ie, pcDNA6.2-GW/ EmGFP-miR-338-5p) and scrambled miRNA (ie, pcDNA6.2-GW/ EmGFP-Ctrl) were constructed using the Block-iT Pol II miR RNAi expressing vector kit (Invitrogen). The pLenti-CMV-miR-338-5p and pLenti-CMV-miR-Ctrl constructs for stable miRNA overexpression were established using the Gateway system (Invitrogen). The pLenti-CMV-puro-DEST empty vector was obtained from Addgene (#17452). Vectors for stable miR-338-5p knockdown (pmiRZip-338-5p) and scrambled control (pmiRZip-Ctrl) were purchased from System Biosciences. For transfection, Lipofectamine 2000 reagent (Invitrogen) was used according to the manufacturer's instructions.
Stable overexpressing and knockdown cell lines were established using lentivirus infection. The virus was packaged using 293T, which was transfected with lentiviral plasmids and packaging mix. The stable cell lines were selected with puromycin. 
| Clinical samples
| Quantitative real-time PCR
Total RNA was extracted using TRIzol reagent according to the manufacturer's protocol (Invitrogen). For serum and Set A tissue samples, cDNA was generated using the miScript II RT Kit (Qiagen) based on the oligo(dT) primer method. Quantitative PCR was undertaken using the miScript SYBR Green PCR Kit (Qiagen). The forward primers used were miR-338-5p-Fwd (5′-gccgaacaatatcctggtgctgagt-3′), 
RNU6B-Fwd
| Western blot analyses
Preparation of whole-cell lysates and immunoblotting were undertaken as described previously. 20 Primary Abs against Id-1, β-actin 
| Dual luciferase reporter assays
The 3′-UTRs of Id-1 containing WT and Mut miR-338-5p binding sites were synthesized by Integrated DNA Technologies. The WTor Mut-3′-UTR was then ligated into psiCHECK-2 vector between XhoI and NotI to generate luciferase reporter vector (psiCHECK-Id-1-3′-UTR-WT/Mut). The luciferase reporter assay was carried out using KYSE150 cells. Briefly, cells were seeded in 24-well plates, and then cotransfected with pcDNA-6. 
| Cell viability assay
Parental ESCC cells and FR cells with manipulated miR-338-5p expression were treated with 20 and 40 μmol/L 5-FU (Calbiochem), respectively, for 48 hours. Cell viability was measured using MTT assay as previously described. 21 Relative proliferation was calculated by normalizing to the corresponding miR-Ctrl or miRZip-Ctrl cells.
| Migration and invasion assays
Wound healing assay was used to monitor migration of ESCC cells. 20 Invasion assay was carried out using Transwell Matrigel-coated invasion chambers with 8-μm pore size polycarbonate filters (BD Biosciences) as described previously. 20 The percentage of sub-G 1 population, indicative of cell death, was analyzed with FlowJo. 22 
| Apoptosis assay
| Animal experiments
| Analysis of public datasets
The expression values of miR-338-5p in the ESCA data cohort were downloaded from the Genomic Data Commons Data Portal, NCI and gastric cancer (GSE93415 and GSE63121) were downloaded from NCBI's GEO.
| Statistical analysis
The data were analyzed using PRISM 5.0 software (GraphPad Software). All the quantitative values were expressed as mean ± SEM. For the in vitro and in vivo experiments, the statistical significance between 2 groups was determined using the unpaired t test. All in vitro experiments were repeated at least 3 times. For quantitative miR-338-5p expression in our clinical samples and in public datasets, differences between 2 groups with nonparametric data (as determined using one-sample Kolmogorov-Smirnov test for normality) were compared using the Mann-Whitney U test. The χ 2 test was used to analyze the association between miR-338-5p expression levels in serum samples and clinicopathological parameters.
Pearson's correlation analysis was used to analyze the relationship between miR-338-5p and Id-1 expression levels in tumor samples.
The association between miR-338-5p expression level and patient survival was plotted using the Kaplan-Meier method, and statistical differences were compared using the log-rank test. Statistical significance level was set at P < .05.
| RE SULTS
| MicroRNA-338-5p directly targets 3′-UTR of Id-1 and modulates Id-1 expression in 5-FU-resistant ESCC cell lines
TargetScanHuman 6.2 and miRanda algorithms were used to look for novel miRNAs that might target the 3′-UTR of Id-1. The prediction results showed that there were 2 putative binding sites for miR-338-5p within the 3′-UTR of Id-1 ( Figure 1A) . The luciferase reporter vectors containing WT and Mut Id-1 3′-UTR were then constructed accordingly ( Figure 1A) , and dual-luciferase reporter assay was carried out to confirm the direct binding of miR-338-5p to the Id-1 3′-UTR. Cotransfection of miR-338-5p and the WT psiCHECK-Id-1 3′-UTR into KYSE150 cells led to a significant decrease (P = .004) of the luciferase signal when compared with scrambled miRNA control ( Figure 1B ). This inhibitory effect was rescued by mutating the 2 predicted miR-338-5p binding sites ( Figure 1B ). These data indicated that Id-1 3′-UTR is a direct target of miR-338-5p. We determined the miR-338-5p expression level in 42 pairs of esophageal tumor and nonneoplastic tissues (Set B samples), which were previously analyzed for Id-1 protein expression. 15 Pearson's correlation analysis showed an inverse relationship (r = −0.214, P = .050) between miR-338-5p and Id-1 ( Figure 1C ).
Our group previously reported that Id-1 can induce chemoresistance in ESCC. 14, 15 We therefore speculated that targeting Id-1 using miR-338-5p could help ESCC cancer cells overcome 5-FU resistance. We found that miR-338-5p was downregulated, whereas Id-1 was upregulated, in KYSE410FR and KYSE150FR cells in comparison with their parental ESCC cell lines (Figure 2A 
| MicroRNA-338-5p overexpression sensitizes 5-FU-resistant ESCC cells to 5-FU treatment in vitro and in vivo
Gain-of-function experiments were carried out to investigate the role of miR-338-5p in 5-FU resistance. The results of MTT cell viability assays showed that overexpression of miR-338-5p sensitized KYSE410FR and KYSE150FR cells to 5-FU treatment, and that this effect was abolished by overexpression of Id-1 ( Figure 3A ). Western blot analyses showed that miR-338-5p expression increased the sen- Tumor xenograft experiments were undertaken to determine whether miR-338-5p overexpression could render ESCC tumors more sensitive to 5-FU treatment in vivo ( Figure 4A ). Comparison of tumor size showed that miR-338-5p overexpression in KYSE150FR cells significantly increased the sensitivity of the tumors to 5-FU therapy, and that concomitant overexpression of Id-1 significantly restored the 5-FU resistance ( Figure 4B ,C).
| MicroRNA-338-5p inhibits ESCC cell invasion and migration by downregulating Id-1
Several studies reported that overexpression of Id-1 is associated with tumor invasion and metastasis in different cancer types, including ESCC. 20, 23, 24 As our data showed that miR-338-5p could downregulate
Id-1, we further speculated that miR-338-5p might play a role in regulating invasion and migration of ESCC cells. The results of the Transwell cell invasion assay indicated that forced expression of miR-338-5p significantly inhibited the invasive activity of ESCC cells in vitro ( Figure 5A ).
MicroRNA-338-5p also reduced the migration activity of ESCC cells, as shown by the wound healing assay ( Figure 5B ). Reoverexpression of Id-1 attenuated these effects ( Figure 5A,B) . Conversely, silencing Figure 5C,D) . These findings suggest that miR-338-5p has metastasisinhibiting functions that are mediated by downregulating Id-1. Figure 6B ). We also analyzed miR-338-5p expression in other cancers of the gastrointestinal tract using public sources including TCGA database and GEO datasets. In TCGA data, the expression level of miR-338-5p in the ESCA data cohort was significantly lower than that in nontumor tissues ( Figure S1A ).
| MicroRNA-338-5p is downregulated in ESCC and other gastrointestinal cancers
Furthermore, comparison of data from paired ESCA tumor and nontumor tissues showed downregulation of miR-338-5p in the majority (10 of 13) of ESCA samples ( Figure S1B ). Taken together, these results suggest an association between miR-338-5p dysregulation and esophageal cancer. In the GEO datasets, lower expression of miR-338-5p was also found in other gastrointestinal cancers ( Figure   S1C -F).
| High serum miR-338-5p predicts better survival and response to neoadjuvant chemoradiotherapy in patients with ESCC
Analysis of TCGA-ESCA data showed that ESCA patients with high miR-338-5p expression in their tumors had longer overall survival time ( Figure S1G ). To determine whether circulating miR-338-5p and miR-16, 25 was first examined in order to minimize experimental variation and ensure accurate detection of biological differences among samples. The results showed that there was no significant difference in the serum miR-16 expression level between patients with ESCC and normal subjects ( Figure S2A ). However, the serum RNU6B level was significantly lower in patients with ESCC ( Figure   S2B ). Therefore, miR-16 was selected as the endogenous control in the analysis of serum miR-338-5p expression. We found that the expression level of serum miR-338-5p in patients with ESCC was significantly lower than that in healthy controls ( Figure 6C ). The cohort of 104 patients with ESCC was then divided into 2 dichotomous groups of high and low serum miR-338-5p expressions using the median as the cut-off value. The patients with high serum miR-338-5p expression had significantly (P = .013) better survival rates (median survival = 58.00 months) than those with low miR-338-5p expression (median survival = 21.57 months) ( Figure 6D ). The advantage of 5-FU and cisplatin-based neoadjuvant therapy in improving the overall survival of ESCC patients is evident from Figure 6E , which shows that patients with pathologic complete response had significantly (P = .001) longer survival (median survival = 108.93 months) than those who did not achieve a complete response (median survival = 30.06 months). Correlation with clinicopathologic parameters showed that expression levels of miR-338-5p in pretreatment serum were inversely correlated with posttherapy pathologic ypT-stage (P = .034), ypM-stage (P = .014), overall pathologic stage (ypTNM; P = .017), and histologic grade (P = .026) ( Table 1 ). Furthermore, high serum miR-338-5p expression was associated with lower percentage of residual viable cells in the primary tumor collected during surgery, and with complete response to therapy (Table 1) , which indicated that higher pretreatment serum miR-338-5p level could predict a better response to chemoradiotherapy.
| D ISCUSS I ON
Development of drug resistance is a major obstacle to the effective treatment of human cancer. Despite 5-FU being an antimetabolic agent widely used in treating gastrointestinal cancers, the response rate of esophageal carcinoma to 5-FU is only 15%. [26] [27] [28] Emerging evidence indicates that miRNAs are associated with chemoresistance, but relatively few miRNAs were experimentally validated to have the ability to regulate the sensitivity of ESCC cells to 5-FU treatment. [10] [11] [12] [29] [30] [31] Our present study found that miR-338-5p was underexpressed in 5-FU-resistant ESCC cells, and that ectopic overexpression of miR-338-5p in these cells could increase their sensitivity to 5-FU treatment both in vitro and in vivo. We further established that miR-338-5p inhibits 5-FU chemoresistance as well as decreases the invasive and migratory potential of ESCC cells through targeting Id-1. Upregulation of Id-1 is a frequent event in chemoresistant and metastatic tumors. [32] [33] [34] The role of Id-1 in cisplatin chemoresistance in esophageal cancer has not been elucidated, but previous studies showed that targeting Id-1 can sensitize human colon cancer-initiating cells to oxaliplatin and suppress the metastatic ability of cancer cells in vivo. 34, 35 Thus, the miR-338-5p/Id-1 regulatory axis could be worth exploring in developing new treatment strategies for Id-1 overexpressing or 5-FU/cisplatin-resistant ESCC. Although miR-338-5p had been reported to be downregulated in non-small-cell lung carcinoma 36 and glioblastoma, 37, 38 we have found that its expression was reduced in the majority of ESCC.
Analysis of GEO datasets showed the same phenomenon in gastric, colon, and rectal cancers, thus suggesting that miR-338-5p has tumor suppressor functions in the gastrointestinal tract. In addition to Id-1, 2 other genes, namely survivin and fermitin family homolog 2 (FERMT2), had been reported to be direct targets of miR-338-5p in ESCC. 39, 40 Intratumoral injection of miR-338-5p mimic could downregulate survivin expression and increase the sensitivity of ESCC tumor xenografts to radiation therapy. 40 Esophageal squamous cell carcinoma cells transfected with miR-338-5p mimic showed reduced cisplatin resistance and cell proliferation and migration. 39 These findings together suggest that miR-338-5p replacement therapy could be a potentially useful approach in esophageal cancer therapy because miR-338-5p can concurrently target multiple effectors that are implicated in chemoradiotherapy resistance.
Circulating miRNAs are potentially useful minimally invasive biomarkers for prognosis. Our results showed that low miR-338-5p levels in serum on admission was significantly associated with poorer survival and advanced posttherapy pathologic staging. Notably, the majority of patients who achieved pathologic complete response to neoadjuvant chemoradiotherapy had high pretreatment serum levels of miR-338-5p.
Taken together, serum miR-338-5p could be a useful predictive marker for response to 5-FU/cisplatin-based neoadjuvant chemoradiation.
Further confirmation in a larger scale study is warranted.
In summary, by combining clinicopathologic and experimental approaches to study the role of miR-338-5p in ESCC, we have provided evidence of its functions and mechanism in reversing 5-FU chemoresistance as well as suppressing cancer cell invasion and migration. 
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